The bottom line: Our findings suggest that GLP-1RA and SGLT2i (and especially SGLT2i with the lowest number needed to treat (NNT) for nearly all study outcomes) may be the preferred glucose-lowering agents for cardiovascular risk reduction in patients at moderate risk for CVD, building on and consistent with existing RCT evidence in the high-risk population. This report highlights potential preference for GLP-1 drugs as a first-line treatment for Type 2 diabetes related to its cardioprotective effect
Federal law permits compounding for products not commercially available, products on the FDA drug shortage list, and medically necessary patient-specific formulations that differ in strength, combination, or vehicle
Clough JD, Rajkumar R, Crim MT, Ott LS, Desai NR, Conway PH, Maresh S, Kahvecioglu DC, Krumholz HM
2 USA Cold-Chain Integrity : While stable at room temperature, NNMT inhibitors can degrade under extreme heat during transit
Gastrointestinal disorders : This medication is contraindicated in patients with a history of severe gastrointestinal diseases
There are many factors to consider when switching and our team of expert clinicians will review your order and ensure you start at the correct dose